Pharmactive, which specializes in the research, development, and extraction of branded natural ingredients, has been experiencing a strong growth and development curve for years. It has logged an average annual sales growth greater than 23%, driven largely by the success of the affron saffron extract and ABG10+, a branded black garlic extract. The company expects sales of €12 million by the end of fiscal 2021.
Siparex’s stake will allow Pharmactive to accelerate its development plans through external growth, and expand its portfolio of natural ingredients and international commercial presence. Approximately 85% of Pharmactive’s global activity occurs in Europe, the U.S., and Asia.
Related: Affron Receives Patent for Mood Support Saffron Linked With Improvements in Menopausal Symptoms HPI Purchases a Stake in Bergamot Manufacturer
“It’s exciting to collaborate with such a well-established PE,” said Jean-Marie Raymond, CEO and Founder of Pharmactive. “This new investment round marks a significant milestone for our company. We experienced expansive growth in 2020, despite the pandemic, and strong sales growth is forecast to continue in 2021.”Pierre Bordeaux Montrieux, Managing Director of Siparex Midcap, stated: “Positioned in a booming market, Pharmactive is an innovative company led by an experienced and enthusiastic Founding Manager.”
Stéphane Agësse, Senior Investment Manager within Siparex Midcap, added: “Pharmactive stands out in particular with its unique validation positioning and systemic scientific analysis of premium products. We are proud to support them in this new phase of development.”
Raymond concluded: “Consumers are seeking science-supported, natural mental wellness solutions and Pharmactive can fulfill this demand and other emerging trends with branded ingredients backed by science. Pharmactive brings innovation, nature, and value to the table, challenging current paradigms.”
